SCHEMBL26430809

SCHEMBL26430809

COCCOCCOCCOCCSC(C)=O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.40
POLB P06746 1/20 0.39
BLM P54132 1/20 0.39
ATM Q13315 1/20 0.39
CA2 P00918 1/20 0.33
ALDH1A1 P00352 3/20 0.31
TSHR P16473 2/20 0.31
HDAC3 O15379 2/20 0.31
HDAC4 P56524 2/20 0.31
HDAC1 Q13547 2/20 0.31
HDAC7 Q8WUI4 2/20 0.31
HDAC2 Q92769 2/20 0.31
HDAC10 Q969S8 2/20 0.31
HDAC11 Q96DB2 2/20 0.31
HDAC8 Q9BY41 2/20 0.31
HDAC6 Q9UBN7 2/20 0.31
HDAC9 Q9UKV0 2/20 0.31
HDAC5 Q9UQL6 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5854800 1.00 CYP2C19 (0.40) CYP2C19POLBBLMATMCA2
SCHEMBL6001508 1.00 CYP2C19 (0.40) CYP2C19POLBBLMATMCA2
SCHEMBL26430803 1.00 CYP2C19 (0.40) CYP2C19POLBBLMATMCA2
SCHEMBL19999151 0.91 CYP2C19 (0.46) CYP2C19POLBBLMATMALDH1A1
SCHEMBL17883360 0.91 CYP2C19 (0.46) CYP2C19POLBBLMATMALDH1A1
SCHEMBL1777653 0.89 CYP2C19 (0.48) CYP2C19POLBBLMATMALDH1A1
SCHEMBL2488440 0.86
SCHEMBL1471178 0.84 ALDH1A1 (0.38) CYP2C19POLBBLMATMCA2
SCHEMBL29518923 0.84 ALDH1A1 (0.38) CYP2C19POLBBLMATMCA2
SCHEMBL888204 0.83 MEN1 (0.48) CYP2C19POLBBLMATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11639350-B2 Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections JANSSEN PHARMACEUTICA NV (BE) 2023-05-02 US disclosed
US-11639350-B2 Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections JANSSEN PHARMACEUTICA NV (BE) 2023-05-02 US disclosed
US-11639350-B2 Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections JANSSEN PHARMACEUTICA NV (BE) 2023-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11639350-B2 Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections HCCS, HAVCR2, NR1H4 CYP2C19 128/4885POLB 135/4885BLM 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.